Agentic AI in Clinical Trials: Where We Are Now and Where We Are Going – Swiss Biotech Day Panel
At the Swiss Biotech Day 2026 in Basel, PSI’s Head of Process Improvement joins biopharma sponsors and technology leaders to examine what agentic AI is delivering in trial execution today, and what realistically comes next. No hype. Real evidence from real programs.
Watch the 45-minute session
Enter your details below to access the full recording.
* indicates required fields
"*" indicates required fields
What you can expect to learn
This is a cross-functional perspective from sponsors and technologists actively working through the same AI implementation challenges.
Sponsor perspectives on what is working
Basilea and Luzsana Biotechnology on where AI has already changed outcomes in live development programs.
Honest accounts of where AI has underdelivered
What the field expected from early agentic AI deployments, and what real implementations revealed.
Infrastructure and capability gaps
What data architecture and knowledge systems need to change before the broader vision is achievable.
AI adjacent-industry lessons
How clinical development draws from AI transformation in finance, logistics, and advanced manufacturing.
Full-panel debate: the questions sponsors are asking
Rapid acceleration in regulated environments · How to measure whether AI is actually working · Who owns the data · Who leads the transformation.
The people in the room
Kirill S. Soldatov
Head of Process Improvement
PSI
Dr. Florian Maurer
Head of Clinical Development
Basilea Pharmaceutica
Sezcan Ozturk
Head of Europe, Vice President
Luzsana Biotechnology
Daniel Morris
Lead Solutions Engineer EMEA
Arango
Dymitro Baikov
Vice President of AI
DataArt
A clinical trial is not a simple sequential linear set of tasks – we need to look at it as a network of interconnected processes. Each of those processes, in turn, has multiple decision points where people need to decide which way to go ... and these decisions within one study are done by multiple people across multiple teams and multiple geographies, which creates an inherent problem of instability in process performance. That's what agentic AI systems promise to solve.
The Operational Reality of Agentic AI in Phase 2–3 Trials
The Swiss Biotech Day panel discussion in written form: where AI is creating documented value today, where it isn’t, and what clinical operations will realistically look like by 2030.
Discuss how agentic AI applies to your specific program
A PSI clinical operations expert can examine site selection, startup strategy, and real-time decision architecture in the context of your trial design and timeline.
